Squamous Cell Carcinoma Suppliers In North America For Served Medical Health Care

Theriva™ is a clinical-stage immuno-oncology company developing oncolytic viruses intended to overcome the protective barrier surrounding solid tumors and selectively kill tumor cells. Our developmental therapies stem from the laboratory of Dr. ...

AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO™s strategy is to focus its resources toward development and commercialization of its product candidates in ...

Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next-generation cancer therapeutics – antibody drug conjugates, bispecific ...

MiraDx partners with universities and pharmaceutical companies to utilize our unique genetic research to help better treat cancer. MiraDx was co-founded by Joanne Weidhaas, M.D., Ph.D. and Frank Slack, Ph.D. whose cutting-edge genetic research ...

Kaio's strategy is to develop and in-license technologies and therapies that enable the body’s own immune system to work more efficiently. The goal is to improve clinical outcomes for patients, increase the number and efficacy of therapeutic options ...

At Kura Oncology, we are committed to realizing the promise of precision medicines for the treatment of cancer. The genomics revolution is transforming how we treat cancer. We now understand that a patient’s response to treatment depends in part on ...

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive, and cost-effective treatments for both oncological and non-oncological conditions. The recently introduced Sculptura robotic ...

Aegle Therapeutics is a first in class, phase 1/2a stage biotechnology company isolating extracellular vesicles including exosomes (EVs) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa ...

Formely known as Onconova Therapeutics, Inc. Traws Pharma is a clinical stage biopharmaceutical company developing small molecule oral product candidates for respiratory viral diseases and cancer. In the viral respiratory disease space, Traws Pharma ...

Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on a proprietary arenavirus platform that is designed to reprogram the body’s immune system. We are using our non-replicating and ...

GeneCentric Therapeutics is applying our proprietary rT(I)ME Explorer Platform to identify high resolution molecular subtypes and drug responder populations that enable the development of precision cancer drugs while improving patient outcomes. Our ...

EDM3 Solutions was formed in October 2019 by three healthcare executives with over 85 years of experience in the industry with the #1 goal of providing the best customer service in healthcare. That same month, these premium quality product lines ...

In April 2018, Digital Diagnostics(formerly known as IDx) became the first company to ever receive FDA clearance for an AI diagnostic platform that makes a diagnosis without physician input at the point-of-care. This achievement did not happen ...

Kailos Genetics provides consumers access to affordable physician-ordered genetic tests. It is our mission to help people take control of their health and make more informed decisions. The Kailos test is an easily accessible genetic test catered to ...

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and ...

Xstrahl is a prominent global provider specializing in the development and delivery of superficial radiation therapy devices and advanced preclinical radiation research systems. The company is actively engaged in connecting experts to further the ...